

Person with cancer—castrate resistance indicator, yes/no code N

Exported from METEOR (AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website's material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at <https://creativecommons.org/licenses/by/4.0/>.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

Person with cancer—castrate resistance indicator, yes/no code N

Identifying and definitional attributes

Metadata item type:	Data Element
Short name:	Castrate resistance indicator
METEOR identifier:	492869
Registration status:	HealthI , Standard 14/05/2015
Definition:	An indicator of whether a person with cancer has been found to have castrate resistance, as represented by a code.
Data Element Concept:	Person with cancer—castrate resistance indicator
Value Domain:	Yes/no code N

Value domain attributes

Representational attributes

Representation class:	Code	
Data type:	Boolean	
Format:	N	
Maximum character length:	1	
	Value	Meaning
Permissible values:	1	Yes
	2	No

Data element attributes

Collection and usage attributes

Guide for use:	Record whether a person is classed as castrate resistant. Castrate resistance is indicated by two consecutive rising PSA levels being found in PSA tests that are at least two weeks apart despite castrate levels of testosterone (<50ng/dL). This element should be recorded in conjunction with Castrate resistance date .
-----------------------	--

Source and reference attributes

Submitting organisation:	Cancer Australia
Reference documents:	National Comprehensive Cancer Network 2013. NCCN Guidelines in Oncology: Prostate Cancer Version 2.2013. National Comprehensive Cancer Network, Fort Washington Scher HI Halabi S Tannock I et al 2008. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 26: 1148-54

Relational attributes

**Related metadata
references:**

See also [Person with cancer—castrate resistance date, DDMMYYYY
Health!](#), Standard 14/05/2015

**Implementation in Data Set
Specifications:**

[Prostate cancer \(clinical\) NBPDS
Health!](#), Standard 14/05/2015